Evidence map›Paper›PMID 42750812›Full record

ArticleiScience2026

Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies.

Pierre Rosenbaum, Cyril Planchais, Timothée Bruel, Maxime Beretta, Isabelle Staropoli, William-Henry Bolland, Florence Guivel-Benhassine, Delphine Planas, French COVID Cohort Study Group, CORSER Study Group and 2 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pierre RosenbaumInstitut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France.
Cyril PlanchaisInstitut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France.
Timothée BruelInstitut Pasteur, Université Paris Cité, Virus & Immunity Unit, Paris, France.
Maxime BerettaInstitut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France.
Isabelle StaropoliInstitut Pasteur, Université Paris Cité, Virus & Immunity Unit, Paris, France.
William-Henry BollandInstitut Pasteur, Université Paris Cité, Virus & Immunity Unit, Paris, France.
Florence Guivel-BenhassineInstitut Pasteur, Université Paris Cité, Virus & Immunity Unit, Paris, France.
Delphine PlanasInstitut Pasteur, Université Paris Cité, Virus & Immunity Unit, Paris, France.
French COVID Cohort Study Group
CORSER Study Group
Olivier SchwartzInstitut Pasteur, Université Paris Cité, Virus & Immunity Unit, Paris, France.
Hugo MouquetInstitut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD) of the spike protein can potently neutralize infection and exert additional antiviral functions. Here, we characterize the functional profiles of human RBD-specific memory B cell antibodies elicited by ancestral SARS-CoV-2 infection. While SARS-CoV-2 neutralizing antibodies, mainly class 1 and 3 anti-RBD antibodies, often lose binding and neutralizing activity against Omicron variants, most non-neutralizers that bind conserved RBD epitopes remain broadly reactive. Despite their restricted cross-reactivity, neutralizing antibodies mediate Fc-effector functions including antibody-dependent cellular cytotoxicity, phagocytosis, and complement deposition. Most neutralizers also enhance binding of antibodies that target the SARS-CoV-2 spike fusion peptide via receptor-mimetic allostery. In contrast, broadly reactive non-neutralizers fail to trigger phagocytic or allosteric effects. Thus, viral escape primarily affects neutralizing, polyfunctional antibodies, whereas cross-reactive non-neutralizing antibodies, which exert limited antiviral effects, may apply minimal immune pressure.

Indexed as

COVID-19Fc-effector functionshuman monoclonal antibodiesmemory B cellsSARS-CoV-2

Identifiers

PMID42750812
PMCPMC13577880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.